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Brain metabolism of amino acids and ammonia in patients with chronic
renal insufficiency. The cerebral metabolism of amino acids (AA) and
ammonia in the postabsorptive state was evaluated in 8 subjects with
normal renal function and in 6 patients with chronic renal insufficiency
(CR1) by measuring the differences between the arterial and the internal
jugular venous concentrations of free AA and ammonia. In normal
conditions, the brain extracts serine, glutamine, proline, glycine, Va-
line, isoleucine, leucine, and lysine. In CR1, cerebral glycine
and uptake increases, valine and isoleucine extraction de-
creases, glutamine uptake disappears, and ammonia extraction be-
comes evident. The cerebral extraction of glycine is correlated with the
arterial concentration of glycine, serine, and branched-chain AA. The
extraction of '/2cystine is correlated with the arterial concentration of
and tyrosine. Finally, the extractions of valine and ammonia
are correlated with the arterial concentration of valine and ammonia,
respectively. It follows that alterations of blood AA and ammonia
concentrations observed in CR1 markedly affect the cerebral uptake of
some AA and ammonia. The lack of cerebral glutamine extraction might
be due to an enhanced production and/or, more likely, to an impaired
utilization of this AA by the brain. Data reported here suggest that in
CR! cerebral nitrogen metabolism is altered; such alterations may play
a pathogenic role in uremic encephalopathy.
Métabolisme cérébra! des acides amines et de l'ammoniaque chez les
malades atteints d'insuffisance rénale chronique. Le m&abolisme céré-
bral des acides aminés (AA) et de l'ammoniaque dans Ia phase post
absorption a été étudié chez 8 sujets ayant une fonction renale normale
et 6 malades atteints d'insuffisance rénale chronique par Ia mesure de Ia
difference de concentration arterio-vieneusejugulaire interne des AA et
de l'ammoniaque. Dans les conditions normales le cerveau extrait Ia
sérine, Ia glutamine, La proline, Ia glycine, Ia valine, Ia cystine,
l'isoleucine, Ia leucine et Ia lysine. Dans I'insuffisance rénale chronique
Ia captation cérébrale de glycine et de '/2 cystine augmente, l'extraction
de valine et d'isoleucine diminue, Ia captation de glutamine disparait et
l'extraction d'ammoniaque devient évidente. L'extraction cérébrale de
glycine est corrélée a Ia concentration artérielle de glycine, de sérine et
des AA a chaine latérale. L'extraction de Ia cystine est corrélée a Ia
concentration artérielle de cystine et de tyrosine. Enfin les extrac-
tions de valine et d'ammoniaque sont corrélées respectivement avec les
concentrations de valine et d'ammoniaque. II en résulte que les
modifications des concentrations sanguines des AA et de l'ammoniaque
observees dans l'insuffisance rénale chronique affectent de facon im-
portante Ia captation cérébrale de certains AA et de l'ammoniaque.
L'absence d'extraction cérébrale de glutamine pourrait être due a une
augmentation de Ia production et/ou, plus probablement, a une utilisa-
tion defectueuse de cet acide amine par le cerveau. Les résultats
rapportés suggerent qu'au cours de l'insuffisance rénale chronique Ic
métabolisme cérébral de l'azote est modiflé. Ces modifications pour-
raient jouer un role pathogenique dans l'encéphalopalhie urémique.
The pathophysiology of uremic encephalopathy is still poorly
understood. Alterations of hydric volumes, of sodium, calcium
and phosphate balances, and the presence of hypertension and
uremic toxins themselves 11—3] may have important pathogenic
roles.
Increased levels of 5-hydroxyindoleacetic acid and homova-
nillic acid in the cerebral spinal fluid (CSF) of uremic patients
[41, and high serotonine and low dopamine contents in the
cerebral tissue of patients who died while in uremic coma have
been reported [5]. In addition, cerebral glucose consumption is
decreased in patients with chronic renal insufficiency (CR1) [6].
More recently, changes of CSF amino acid (AA) conceritra-
tions, unrelated to alterations in their blood concentrations,
have been detected in patients with CR! [7]. The all data clearly
suggest that cerebral metabolism, including AA and neurotrans-
mitter metabolism, is altered in renal insufficiency.
The concentration of AA in the blood is one of the major
factors controlling their transport into the brain [8, 9]. In CR!,
the arterial blood concentration of several AA's is altered quite
early and in the absence of malnutrition [10]. Accordingly,
these concentration changes may affect AA's entry into the
brain and, consequently, cerebral AA metabolism. It may be
hypothesized that such alterations play an important role in the
pathophysiology of uremic encephalopathy.
Studies reported here were undertaken to investigate cerebral
AA and ammonia metabolism in patients with CR!, by measur-
ing the arteriovenous difference of these metabolites across the
brain.
Methods
Patients. Two groups of patients were studied. The first
group consisted of eight patients, aged 29 toSS yr, with cardiac
valvular diseases. Routine laboratory tests, acid-base and elec-
trolyte measurements, and renal function tests were normal. In
these patients, a right-sided cardiac catheterization was consid-
ered necessary for diagnostic hemodynamic evaluation.
The second group consisted of six patients, aged 22 to 56 yr,
with chronic glomerulonephritis and renal insufficiency. Azote-
mia had been present from 3 to 36 months. GFR was 18.9 3.5
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Table 1. Arterial concentrations and arterial-jugular venous differences of free amino acids and ammonia in 8 subjects with normal renal
function and in 6 patients with chronic renal insufficiency (CR1)
Values are given as the means SEM.
b Probability that patients with CR1 do not differ from controls
Enzymatically determined.
d Determined only in 7 subjects.
Determined in 2 additional patients
Probability that A-V difference does not differ from zero: P < 0.05; P <0.025; h P < 0.01; P < 0.005; P < 0.001.
mi/mm • 1.73 m2; blood urea was 21.2 2.4 mmoles/liter;
arterial bicarbonate was 17.4 0.9 mmoles/liter; and hemato-
crit was 32.8 1.7%. Serum sodium and potassium, and serum
albumin were in the normal range. Three patients showed bone
alterations that were more severe than could be expected on the
basis of the degree and the duration of their renal insufficiency
and that were attributed to hyperparathyroidism. Innominate,
internal jugular, and thyroid vein catheterization for parathor-
mone measurements was carried out to localize the hyperfunc-
tioning parathyroid tissue, in view of a possible parathyroidec-
tomy. The other three patients had cardiac valvular diseases,
and a right-sided cardiac catheterization was considered neces-
sary for diagnostic hemodynamic evaluation.
Neither group of patients had history or evidence of neuro-
logic disorders, congestive heart failure, hepatic or pulmonary
diseases, or diabetes mellitus. All patients were on a diet that
provided 35 to 40 kcal and 0.8 to 0.9 g of protein per kilogram of
body wt per day. They were in good nutritional balance and
were actively employed at the time of the study.
All patients were informed of the nature, purpose, procedure,
and possible risks before their voluntary consent was obtained.
Procedure. All patients were studied in the postabsorptive
state. A teflon catheter was inserted percutaneously into a
peripheral artery. A Cournand no. 6 or 7 F catheter (USCI
International, Murray Hill, New Jersey) was then guided under
fluoroscopic control through an anteeubital vein to the superior
bulb of an internal jugular vein or to the right ventricular cavity.
During the removal of the catheter from the ventricular cavity,
it was inserted into the superior bulb of an internal jugular vein.
The position of the catheter was ascertained visually with image
intensifIcation before each blood withdrawal. The catheters
were kept patent by flushing with saline intermittently. From
each subject, two or three sets of blood samples were obtained
simultaneously from a peripheral artery and an internal jugular
vein for the measurement of arterial-jugular venous (A-V)
differences of AA and ammonia. Blood was withdrawn by
heparinized syringes kept in ice. Arterial blood pressure and
electrocardiogram were continuously monitored during the
study.
Analysis. The methods used for preparation of samples and
determination of whole blood AA's are reported elsewhere [11].
Lithium buffers instead of sodium buffers were used for AA
analyses in this study. Accordingly, treatment of the whole
blood supernate with sodium suiphite was omitted. Aspartate
was measured on supernate buffered up to a pH of 7 immediate-
ly after the deproteination, and stored at —25°C. The assay was
performed at least 20 days after the withdrawal to avoid the
overlapping of the glutathione peak with the aspartate peak.
Glutamine and glutamate were measured enzymatically, as
reported elsewhere [11].
Ammonia was determined on whole blood. Samples were
deproteinized at +4° C with 0.3 M sodium tungstate and 0.5 M
sulphuric acid immediately after the withdrawal. The protein-
free supernate was stored at —25° C and assayed according to
Chaney and Marbach [12] within 12 hours. An eightfold concen-
tration of phenol and hypochlorite reagents was used. Blanks,
samples, and standards were all in triplicate.
Sodium thiosuiphate method was used for GFR measurement
according to Brun [13]. Urea was determined enzymatically
[12]. Arterial blood pH and Pco2 were estimated at 37° C with
In controls
Arterial concentrations, p.rnoles/liier
In CR1 In controls
A-V differences, p.mo!eslliter
In CR1
Taurine 207.2 18.57 216.6 30,78 NS + 7.9 4.73 + 0.6 6.14 NS
Aspartate 118.4 + 11.43 80.6 10.06 <0.05 + 2.1 1.16 + 2.1 2.44 NS
Threonine 108.2 7.67 107.1 -'- 9.69 NS + 2.0 1,05 + 3.9 1.81 NS
Serine 117.6 5.92 99.3 4.75 <0.05 + 3.7 1.14° + 3.4 l.24 NS
Asparagine 53.0 4.93 59.3 7.57 NS + 0.9 0.71 — 0.1 0.99 NS
Glutamate° 148.1 9.66 138.7 9.84 NS + 2.3 1.09 — 0.5 2.47 NS
Glutamine' 530.0 19.55 495.7 26.49 NS + 13.4 4.46 — 1.0 4.05 <0.05
Proline 131.1 12.68 212.6 24.06 <0.01 + 6.1 ÷ 1,66k + 5.6 1.46' NS
Glycine 263.0 13.06 300.9 17.02 <0.01 + 5.2 l.09'° + 11.7 2.79w <0.05
Alanine 210.0 15.14 272.0 + 24.78 <0.1 — 0.1 + 1.49 + 0.6 3.63 NS
Citrulline 32.1 2.47 61.4 5.30 <0.001 + 1.6 0.72 1.5 0.74 NS
Valine 182.0 4.89 154.4 12.69 <0.05 + 9.0 1.69' + 4.0 1.26 <0.05
Cystine 45.9 4.65 83.8 7.23 <0.001 + 2.9 0.33' + 6.2 1.53" <0.025
Isoleucine 49.9 1.67 47.6 6.48 NS + 3.1 0.60' + 1.5 0.581 <0.1
Leucine 97.7 2.89 86.4 10.09 NS + 6.1 0.70' + 4.8 0.57' NS
Tyrosine 41.8 2.18 32.2 3.75 <0.05 + 0.7 0.56 — 0.1 0.38 NS
Phenylalanine 41.2 1.86 49.1 - 6.30 NS + 1.3 + 0.60 + 1.2 0.59 NS
Ornithine 73.2 4.65 70.8 4.34 NS + 1.1 0.52 + 3.0 1.40 NS
Lysine 142.7 8.00 144.5 10.18 NS + 3.2 0.96 + 3.6 1.59t NS
Histidine 66.8 2.46 85.0 6.46 <0.025 + 1.3 0.57 + 0.4 1.41 NS
Arginine 62.0 3.80 66.9 + 5.38 NS + 1.9 1.01 — 1.3 1.41 NS
Ammonia 43.7 4.01 69.5 7.64 <0.025 — 1.0 + 1.16 + 9.0 3.80° <0.05
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PHM-72 BMS-3 apparatus (Radiometer Co., Copenhagen, Den•
mark). Arterial bicarbonate was calculated using the Hender-
son-Hasselbalch equation. Hematocrit was determined by a
microcapillary procedure.
The nitrogen balance across the brain was calculated by
adding the nitrogen contributed by individual AA and ammonia
which were significantly extracted by the brain.
Controls and patients with CR1 were compared by analysis of
variance by using a completely randomized design; a random-
ized block design was applied to the analysis of variance for the
paired data [14]. Analysis of simple regression and correlation
[14] was used to evaluate the dependence of A-V differences of
each AA on: (a) its arterial concentration; (b) the ratio of its
concentration to the concentration of each individual AA that is
assumed to be in competition for the same transport system
across the blood-brain barrier (BBB) [15]; and (c) the ratio of its
arterial blood concentration to the sum of the concentration of
all AA that are assumed to be in competition for transport.
Analysis of multiple regression [14] was used to estimate the
dependence of A-V differences of each AA on the arterial AA
concentrations that show a simple correlation with the A-V
differences, as obtained from analyses carried out according to
a and b. The relationship between A-V differences of ammonia
and its arterial blood concentration was studied by analysis of
simple regression and correlation. Analyses of simple and
multiple regression were carried out by considering subjects
with normal renal function and patients with CR1 as a single
group. Values are given as the means SEM. The absolute rates
of metabolite exchanges across the brain could not be calculat-
ed because blood flow was not measured.
Results
In normal conditions, the brain significantly extracts serine,
glutamine, proline, glycine, valine, isoleucine, leu-
cine, and lysine from the arterial blood (Table 1). In patients
with CR1, exchanges of serine, proline, leucine, and lysine
across the brain are not different from controls. Conversely,
glycine and V2cystine uptake significantly increases, valine and
isoleucine extraction significantly decreases, glutamine uptake
disappears, and a significant ammonia extraction, not observed
in normal subjects, becomes evident (Table I). Both in normal
conditions and in CR1 there is an excess in the nitrogen
extracted by the brain of 69.4 9.86 p.moles/liter (P < 0.001)
and 53.5 5.25 moles/liter (P < 0.001), respectively.
In patients with CR1, there are increases in arterial concen-
tration of proline, glycine, alanine, citrulline, V2cystine, histi-
dine and ammonia, whereas there are decreases of aspartate,
serine, valine, and tyrosine (Table I).
The A-V difference of glycine shows a linear relationship with
its arterial concentration (P < 0,025) (Fig. 1A), and with the
ratio of [glycine]a to [neutral AA]a (P < 0.01), mainly [serine]a
plus [BCAA]a1 (P < 0.005) (Fig. 1B). The multiple regression
equation of the A-V difference of glycine on [glycine]a, [ser-
ine]a, and [BCAA]a is: glycine A-V difference = 8.370 + 0.100
[glycineja —0.187 [serine]a —0.024 [BCAA]a, (P < 0.01). The
individual regression coefficients are statistically significant (P
<0.05, P < 0.001, and P < 0.05, respectively). The equation
'BCAA denotes the branched chain amino acids (leucine, isoleucine
and valine). The brackets with subscript a signify the arterial concentra-
tion.
—5
y = —10.397 + 27.933x )r = 0.780; P <0005)
y —16.690 + 0.089x )r 0.664; P <0.025)
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Glycine, pmo/es/Iiter Gycine/serino + BCAA
Fig. 1. Relationships between glvcine A-V di:ffrence and A arterial
glycine concentration and B the ratio of arterial glycine to the sum of
arterial concentrations of serine and branched-chain amino acids
(BCAA) in 7 subjects with nor/na! rena/function (solid circles) and in 6
patients with chronic renal insitfficiencv (open circles).
.
I I it
indicates that a 1-ii.mole/liter decrease of [serinela and [BCAAIa
is on the average associated respectively with a 0.187- and
0.024-p.mole/liter increase of A-V differences of glycine; more-
over, a l-mole/liter increase of [glycinela is on the average
associated with a 0.1 -mole/liter increase of the A-V difference
of glycine.
The A-V difference of valine is exponentially related to its
concentration in arterial blood (P < 0.02) (Fig. 2). The exponen-
tial trend of this relationship cannot be explained. The A-V
difference of valine shows a significant relationship with the
ratio of [valinela to [neutral AMa (P < 0.02). But, analysis of
multiple regression indicates that, in subjects reported here,
only the changes of [valine]a markedly affect the variations of
the A-V difference of valine.
The A-V difference of l/2cystine shows a linear relationship
with its arterial concentration (P < 0.01) (Fig. 3A), and with the
ratio of [V2cystinela to [neutral AAIa (P < 0.01), mainly [tyro-
sine]a among the others (P < 0.005) (Fig. 3B). The multiple
regression equation of the ¼cystine A-V difference on [(/2cys-
tinela and [tyrosineja is: l/2cystine A-V difference = 4.261 +
0.078 [Y2cystineja —0.121 [tyrosineja, (P < 0.01). The individual
(A)+25
8
=0
. i+15
+5
(B)
.
0
S •
+20
0
'a
=
E +150a
>.s
+10
>
+5
y = 0.2158 eOl9b0 )r = 0.660; P <0.02)
S
120 140 160 180 200 220
Va ne, ji.moles/Iiter
Fig. 2. Relationships between va/me A-V difference and arterial va/inc
concentration in 8 subjects with normal renal function (solid circles)
and in 6 patients with chronic renal insufficiency (open circles).
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regression coefficients are statistically significant (P < 0.05 and
P < 0.05, respectively). The equation demonstrates that a 1-
p.mole/liter decrease of [tyrosineja is on the average associated
with a 0.121-pmole/liter increase of the A-V difference of
V2cystine; furthermore a l-mole/liter increase of [V2cystine] is
on the average associated with a 0.078-ji.mole/liter increase in
the A-V difference of
Finally, the A-V difference of ammonia is linearly correlated
with its arterial concentration (P < 0.001) (Fig. 4).
Discussion
Findings presented here demonstrate that in normal man, in
the postabsorptive state, the brain takes up serine, glutamine,
proline, glycine, valine, V2cystine, isoleucine, leucine, and
lysine from arterial whole blood. Glutamine and valine uptakes
account for 44% of the total AA extraction by the brain. These
findings partially confirm previous data obtained from plasma
[16] and whole blood measurements [17]. The major discrepan-
cy is the extraction of ¼cystine observed in our study. In
addition, our data demonstrate that the brain extracts glutamine
from whole blood, as already shown from plasma measure-
ments [18]. As previously reported [19], in normal conditions
there is no significant uptake of ammonia by the brain.
In CR!, exchanges across the brain are altered for glutamine,
glycine, valine, Y2cystine, isoleucine, and ammonia. These
alterations are observed even in patients with relatively high
residual GFR, in good general health, well-nourished, and
actively employed. Furthermore, no patient presented obvious
neurologic abnormalities. Because cerebral blood flow is nor-
mal or only slightly increased in patients with CR1 [6, 201, the
abnormalities of cerebral AA and ammonia metabolism detect-
ed in CR! cannot be accounted for by variations of cerebral
blood flow induced by this condition. Moreover, the magnitude
of the variations (both increase and decrease) of A-V differ-
ences of AA's and ammonia observed in CR! may quite unlikely
be due to cerebral blood flow changes.
The transport of AA from the arterial blood into the brain is
controlled by three factors: cerebral blood flow, the BBB
permeability, and blood concentration of AA [211. In the rat,
the AA transport across the BBB takes place through three
y —17.356 + 0.377x (r = 0.844; P <0.001)
..
•o
0
y = —0.516 + 2.918x (r = 0.765; P <0.005)
y= —0.913 + 0.084x(r= 0.687; P< 0.01) +30
(A) (B)
f12 +250 0
+10
+20
+15
+4
0 0
'- +2 +5
0
Cystine/tyrosine
Fig. 3. Relationships between A-V difference and A arterial
'/2cystine concentration and B the ratio of arterial to arterial
yrosine concentration in 8 subjects with normal renal function (solid
circles) and in 6 patients with chronic renal insufficiency (open circles).
.
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30 70 110
S
Cystine, pnio/es/Iiter
0.6 1.8 3.0 S
.
S
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Fig. 4. Relationships between ammonia A-V difference and arterial
ammonia concentration in 8 subjects with normal renal function (solid
circles) and in 8 patients with chronic renal insufficiency (open circles).
major specific carrier systems for the transport of neutral,
basic, and acidic AA's [15]. Data obtained in the same animal
indicate that changes in blood AA concentrations markedly
affect the AA entry into the brain [22—251.
Results presented here demonstrate that alterations in arterial
AA concentration observed in CR1 affect cerebral uptake of
some AA's. Thus, increased arterial glycine induces an in-
creased cerebral uptake of this AA. The cerebral uptake of
glycine is also facilitated by the decreased arterial concentra-
tion of serine and BCAA, which are likely to be in competition
with glycine for the neutral AA transport system [151. In
addition, in the presence of an augmented arterial /2cystine, the
brain takes up this AA in larger amounts. Such an uptake is also
increased by the reduced arterial concentration of tyrosine,
which probably competes with Y2cystine for the neutral AA
transport system [15]. Finally, the decreased arterial concentra-
tion of valine is the major factor for the low cerebral uptake of
this AA. It can be supposed that more severe alterations in
arterial AA concentration, as found in the presence of malnutri-
tion and/or advanced uremia [26, 27], may cause more striking
changes of cerebral AA uptake than do those detected in
patients studied here.
An interesting finding is the cerebral ammonia extraction
observed in CR!, as previously reported [281. The appearance
of such an extraction is due to the slight increase in arterial
ammonia, already suspected in CR1 [10], A similar observation
has been reported in patients with liver failure [29].
The lack of cerebral glutamine uptake, previously shown by
measuring this AA on plasma [18], is a major change observed
in patients with CR!. This defect in cerebral glutamine uptake,
in association with ammonia extraction, might be due to an
increased synthesis of glutamine by the brain, analogously to
that occurring in hepatic [30, 31] and respiratory [32] insuffi-
ciency. But, in contrast to what has been observed in these two
last conditions [33—35], the ratio of CSF glutamine to plasma
glutamine is low in CR! [7] and does not support the hypothesis
that an increased production of glutamine by the brain entirely
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accounts for the disappearance of the cerebral uptake of this
AA. An impaired utilization of glutamine by the brain is more
probable. The low ratio of CSF glutamine to plasma glutamine
might suggest a decreased transport of glutamine across the
BBB and a consequent skip of cerebral utilization of this AA.
But, a defective degradation of glutamine by cerebral tissue, as
observed in other organs [10, 11, 18, 361, cannot be ruled out. It
must be pointed out that no correlation between the A-V
differences of glutamine and the arterial concentration of gluta-
mine or any other neutral AA was detected in this study
Consequently, the defective transport of glutamine into the
brain does not seem to be accounted for by the alterations in
blood AA concentration observed in CR!.
The excess in the nitrogen extracted by the brain both in
normal conditions and in patients with CR! suggests that the
brain releases similar amounts of nitrogen in compounds not:
detectable by the methods used in this study; in fact nitrogen
balance across the brain must be at equilibrium.
The functional sequel of the alterations in the AA exchanges
across the brain observed in CR1 is unknown. These alterations
may bring about changes and imbalances to the cerebral content
of AA, and brain metabolism may be altered. It is known that
glutamine is a major exogenous source for glutamate and -y-
aminobutyric acid formation by cerebral cells [37, 38], and that
glycine is an important neurotransmitter [39]. Moreover, the
BCAA supply to the brain is important for protein, lipid, and
glutamate synthesis, and for fuel provision [40—45]; in children.
and in rats, isoleucine and valine deficiency produces neurolog-
ic symptoms and cerebral lesions [45—47]. Furthermore, cere-
bral ammonia extraction may interfere with cerebral metabo-
lism similarly, even if to a much lesser extent, to that occurring
in hepatic insufficiency.
In conclusion, the changes of cerebral metabolism observed
in patients with CR1 may play a pathogenic role in uremic
encephalopathy.
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